Literature DB >> 29959168

Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose.

Daniel Candotti1, Sonny Michael Assennato2, Syria Laperche1, Jean-Pierre Allain2, Snezna Levicnik-Stezinar3.   

Abstract

OBJECTIVE: HBV infection by blood components is currently prevented in most developed countries by combining sensitive HBV surface antigen (HBsAg) assays, nucleic acid testing (NAT) and in a few of them antibodies against the HBV core antigen (anti-HBc) screening. HBV transmissions by blood components from three repeat donors tested negative for HBsAg and HBV DNA with a highly sensitive screening test (limit of detection (LOD): 3.4 IU/mL) were investigated.
DESIGN: 30 of the 47 recipients of components produced from these three donors were examined. Transfusion transmission was confirmed by phylogenetic analysis of viral sequences obtained from recipients and donors following viral particle concentration.
RESULTS: 9 of 31 (29%) recipients were infected: 7 infections were related to 200 mL of fresh frozen plasma and 2 infections to red blood cells containing 20 mL plasma. Transfusion transmission was confirmed by >99% identity of donor/recipient sequences in five cases, probable in three and possible in one. HBV active infection remained unsuspected for 24-57 months in three recipients. Five non-infected recipients carried anti-HBs when transfused. Six patients transfused with platelet concentrates treated with a pathogen reduction method were not infected. These data enabled to revise previous estimate of the minimal infectious dose from approximately 100 to 16 copies (or 3 IU) of HBV DNA.
CONCLUSIONS: HBV transfusion transmission from occult HBV infection carrying extremely low viral loads is related to plasma volume transfused and possibly prevented by anti-HBs. HBV blood safety could be further improved by either anti-HBc screening, HBV DNA NAT with a LOD of 0.8 copies/mL (0.15 IU/mL) or pathogen reduction of blood components. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Chronic Viral Hepatitis; Diagnostic Virology; Hepatitis B; Transfusion-transmitted Infectious Disease

Mesh：

Substances：

Year:  2018        PMID： 29959168     DOI： 10.1136/gutjnl-2018-316490

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  21 in total

1.  Excluding Occult Hepatitis B Infection before Assigning False-Positive Status to Non-Repeatable NAT Reactivity: Concerning Stolz et al. "Safe-Testing Algorithm for Individual-Donation Nucleic Acid Testing: 10 Years of Experience in a Low-Prevalence Country" [Transfus Med Hemother. 2019 Apr;46(2):104-10].

Authors:  Claire E Styles; Anthea Cheng; Veronica C Hoad; Philip Kiely; Michael Watson; Clive R Seed
Journal:  Transfus Med Hemother       Date:  2019-08-29       Impact factor: 3.747

2.  Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018.

Authors:  Claudio Velati; Luisa Romanò; Ilaria Pati; Giuseppe Marano; Vanessa Piccinini; Liviana Catalano; Simonetta Pupella; Stefania Vaglio; Eva Veropalumbo; Francesca Masiello; Giulio Pisani; Giuliano Grazzini; Alessandro Zanetti; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

3.  Occult hepatitis B infection among blood donors from Yaoundé, Cameroon.

Authors:  Diderot Fopa; Daniel Candotti; Claude T Tagny; Camille Doux; Dora Mbanya; Edward L Murphy; Hany I Kenawy; Farha El Chenawi; Syria Laperche
Journal:  Blood Transfus       Date:  2019-11       Impact factor: 3.443

4.  Occult Hepatitis B Infection among Hemodialysis in Tabriz, Northwest of Iran: Prevalence and Mutations within the S Region.

Authors:  Narges Eslami; Vahdat Poortahmasebi; Javid Sadeghi; Reza Ghotaslou; Bahram Niknafs; Hossein Bannazadeh Baghi; Mahin Ahangar Oskouee
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-06-28       Impact factor: 2.585

Review 5.  A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.

Authors:  Anna Kramvis; Kyong-Mi Chang; Maura Dandri; Patrizia Farci; Dieter Glebe; Jianming Hu; Harry L A Janssen; Daryl T Y Lau; Capucine Penicaud; Teresa Pollicino; Barbara Testoni; Florian Van Bömmel; Ourania Andrisani; Maria Beumont-Mauviel; Timothy M Block; Henry L Y Chan; Gavin A Cloherty; William E Delaney; Anna Maria Geretti; Adam Gehring; Kathy Jackson; Oliver Lenz; Mala K Maini; Veronica Miller; Ulrike Protzer; Jenny C Yang; Man-Fung Yuen; Fabien Zoulim; Peter A Revill
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-20       Impact factor: 73.082

6.  Alternative hepatitis B virus DNA confirmatory algorithm identified occult hepatitis B virus infection in Chinese blood donors with non-discriminatory nucleic acid testing.

Authors:  Xuelian Deng; Xiaohan Guo; Tingting Li; Syria Laperche; Liang Zang; Daniel Candotti
Journal:  Blood Transfus       Date:  2020-12-17       Impact factor: 3.443

7.  Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia.

Authors:  Yesim Aydinok; Antonio Piga; Raffaella Origa; Nina Mufti; Anna Erickson; Anne North; Katie Waldhaus; Christine Ernst; Jin-Sying Lin; Norman Huang; Richard J Benjamin; Laurence Corash
Journal:  Br J Haematol       Date:  2019-05-30       Impact factor: 6.998

8.  Identification and characterization of lncRNA AP000253 in occult hepatitis B virus infection.

Authors:  Qingqin Hao; Zheng Wang; Qinghui Wang; Bo Chen; Huizhong Qian; Xiao Liu; Hong Cao; Wei Xia; Jian Jiang; Zhonghua Lu
Journal:  Virol J       Date:  2021-06-10       Impact factor: 4.099

Review 9.  Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.

Authors:  Marion C Lanteri; Felicia Santa-Maria; Andrew Laughhunn; Yvette A Girard; Marcus Picard-Maureau; Jean-Marc Payrat; Johannes Irsch; Adonis Stassinopoulos; Peter Bringmann
Journal:  Transfusion       Date:  2020-04-24       Impact factor: 3.157

10.  Reduction of the occurrence of occult HBV infection in infants by increasing the dose of hepatitis B vaccine: a large prospective cohort study.

Authors:  Authors Yi Li; Zhixiu Liu; Yarong Song; Yiwei Xiao; Jing Jiang; Lili Li; Xiangjun Zhai; Jianxun Liu; Zhongping Duan; Feng Ding; Jia Liu; Hui Zhuang; Liguo Zhu; Jie Jiang; Huaibin Zou; Jie Wang; Jie Li
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.